Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enovis Corp (ENOV)

Enovis Corp (ENOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,730,539
  • Shares Outstanding, K 57,189
  • Annual Sales, $ 2,108 M
  • Annual Income, $ -825,490 K
  • EBIT $ 76 M
  • EBITDA $ 1,011 M
  • 60-Month Beta 1.67
  • Price/Sales 0.76
  • Price/Cash Flow 1.46
  • Price/Book 0.79

Options Overview Details

View History
  • Implied Volatility 60.17% ( -0.11%)
  • Historical Volatility 52.81%
  • IV Percentile 63%
  • IV Rank 43.28%
  • IV High 86.15% on 08/05/25
  • IV Low 40.34% on 11/29/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 51
  • Volume Avg (30-Day) 510
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 9,139
  • Open Int (30-Day) 7,866

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.83
  • Number of Estimates 2
  • High Estimate 0.85
  • Low Estimate 0.81
  • Prior Year 0.98
  • Growth Rate Est. (year over year) -15.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.52 +14.50%
on 11/07/25
34.28 -8.08%
on 10/27/25
+1.82 (+6.13%)
since 10/10/25
3-Month
27.52 +14.50%
on 11/07/25
34.28 -8.08%
on 10/27/25
+3.40 (+12.10%)
since 08/11/25
52-Week
25.47 +23.74%
on 08/04/25
49.75 -36.66%
on 12/04/24
-15.84 (-33.45%)
since 11/11/24

Most Recent Stories

More News
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

ENOV : 31.51 (+4.13%)
CORT : 79.01 (+4.66%)
LNTH : 53.37 (+5.29%)
EVH : 5.04 (+1.82%)
RGEN : 153.44 (+5.34%)
3 Healthcare Stocks We Approach with Caution

3 Healthcare Stocks We Approach with Caution

ENOV : 31.51 (+4.13%)
HSIC : 73.22 (+0.30%)
CRL : 173.50 (+2.68%)
ENOV Q3 Deep Dive: Portfolio Streamlining and Innovation Drive Amid Margin Headwinds

ENOV Q3 Deep Dive: Portfolio Streamlining and Innovation Drive Amid Margin Headwinds

ENOV : 31.51 (+4.13%)
Enovis’s (NYSE:ENOV) Q3 Sales Top Estimates

Enovis’s (NYSE:ENOV) Q3 Sales Top Estimates

ENOV : 31.51 (+4.13%)
Enovis: Q3 Earnings Snapshot

Enovis: Q3 Earnings Snapshot

ENOV : 31.51 (+4.13%)
Enovis Announces Third Quarter 2025 Results

Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically...

ENOV : 31.51 (+4.13%)
Enovis (ENOV) Q3 Earnings: What To Expect

Enovis (ENOV) Q3 Earnings: What To Expect

ENOV : 31.51 (+4.13%)
Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today it will...

ENOV : 31.51 (+4.13%)
1 Russell 2000 Stock Worth Your Attention and 2 We Avoid

1 Russell 2000 Stock Worth Your Attention and 2 We Avoid

ENOV : 31.51 (+4.13%)
ROAD : 110.43 (-3.26%)
SKIN : 1.3100 (-5.07%)
1 Unprofitable Stock to Own for Decades and 2 Facing Challenges

1 Unprofitable Stock to Own for Decades and 2 Facing Challenges

ENOV : 31.51 (+4.13%)
WBTN : 16.48 (-1.79%)
AMCX : 7.80 (-3.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Enovis Corporation is a medical technology company. Its range of products, services and integrated technologies fuel active lifestyles in orthopedics and beyond. Enovis Corporation, formerly known as Colfax Corporation, is based in Wilmington, DE.

See More

Key Turning Points

3rd Resistance Point 32.86
2nd Resistance Point 32.19
1st Resistance Point 31.85
Last Price 31.51
1st Support Level 30.85
2nd Support Level 30.18
3rd Support Level 29.84

See More

52-Week High 49.75
Fibonacci 61.8% 40.47
Fibonacci 50% 37.61
Fibonacci 38.2% 34.74
Last Price 31.51
52-Week Low 25.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar